
PLT Response

The median follow-up time in all patients was 25 (IQR, 14-68 weeks); 27 (IQR, 15-71 weeks) in the eltrombopag arm and 22 (IQR, 12-52 weeks) in the placebo arm. PLT-R was observed in 47 (42.3%) eltrombopag recipients, of whom 31 (66.0%) showed a complete response, compared with six (11.1%; none were complete) in 54 placebo recipients (odds ratio, 5.9; 95% CI, 2.3 to 14.9; Reverse Kaplan-Meier curves of platelet response in both treatment groups.The median daily drug dose at response was 50 (IQR, 50-150 mg). All responsive patients required dose titration during the first 6 months. Each titrated dose over the whole study period is summarized in the Data Supplement (Table S1). Median PLT increment at best response in the first 24 weeks was significantly higher in the eltrombopag (31; IQR, 8-103 × 10(A) Box and whisker plot of PLT count over time. The horizontal line in the middle of each box represents the median, while the top and bottom of each box represent the 75th and 25th percentiles, respectively. The whiskers above and below the box plot mark the 97.5th and 2.5th percentiles, respectively. (B) Hemoglobin as an effect modifier of PLT response (log-transformed data) to eltrombopag. Data represent the ratio (and 95% CI) over the study period of the geometric mean of PLT count in eltrombopag-treated patients to the geometric mean of PLT count in patients in the placebo group. The numbers reported in parentheses (B) represent the number of observations with a hemoglobin value over time falling in a specific hemoglobin interval. LMM, linear mixed models; PLT, platelet.In a linear-mixed model, hemoglobin was found to modify the PLT-R to eltrombopag, with the between-treatment difference in PLT count over the trial period being closely related to hemoglobin levels (Fig 